Finance

Lists
ABBV:NYSE
AbbVie Common Stock
261,59 US$
-0,65%
(-1,70) 1D
262,98 US$
+0,53% (+1,39)
After hours
Closed: 30 სექ, 16:03:56 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV...
Open
264,60 US$
High
265,36 US$
Low
261,59 US$
Mkt. cap
462,26 მლრ.
Avg. vol.
4,22 მლნ.
Volume
0,00
Dividend
2,65%
Quarterly dividend
1,73 US$
Ex-dividend date
15 ოქტ. 2026
P/E ratio
73,99
52-wk high
269,39 US$
52-wk low
190,75 US$
EPS
3,54 US$
Beta
0,29
Shares outstanding
1,77 მლრდ.
No. of employees
57 ათ.
Open
264,60 US$
High
265,36 US$
Low
261,59 US$
Mkt. cap
462,26 მლრ.
Avg. vol.
4,22 მლნ.
Volume
0,00
Dividend
2,65%
Quarterly dividend
1,73 US$
Ex-dividend date
15 ოქტ. 2026
P/E ratio
73,99
52-wk high
269,39 US$
52-wk low
190,75 US$
EPS
3,54 US$
Beta
0,29
Shares outstanding
1,77 მლრდ.
No. of employees
57 ათ.
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEOრობერ ეი მაიკლ
Employees57 ათ.
Founded10 აპრ. 2012
HeadquartersNorth Chicago, ილინოისი, ამერიკის შეერთებული შტატები
Sector-
Websiteabbvie.com
Analyst ratings
Based on 23 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current 261,59 US$
315,00 US$ (+20,42%)
Average
281,67 US$ (+7,68%)
Lowest
225,00 US$ (-13,99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Trung Huynh
RBC Capital
Buy
Maintained
280,00 US$
+7%
09/29/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
290,00 US$
+10,9%
09/28/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
300,00 US$
+14,7%
09/29/2026
Geoff Meacham
Citi
Hold
Maintained
260,00 US$
-0,6%
09/29/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
289,00 US$
+10,5%
09/29/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/28/2026
Steve Scala
TD Cowen
Buy
Maintained
280,00 US$
+7%
09/28/2026
Chris Schott
J.P. Morgan
Buy
Maintained
285,00 US$
+8,9%
09/25/2026
David Amsellem
Piper Sandler
Buy
Reiterated
303,00 US$
+15,8%
09/23/2026
Louise Chen
Scotiabank
Buy
Maintained
280,00 US$
+7%
09/22/2026
Luisa Hector
Berenberg Bank
Buy
Reiterated
275,00 US$
+5,1%
09/10/2026
Rajesh Kumar
HSBC
Buy
Maintained
315,00 US$
+20,4%
09/10/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
282,00 US$
+7,8%
09/08/2026
William Katz
TD Cowen
Buy
Reiterated
280,00 US$
+7%
09/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
300,00 US$
+14,7%
08/17/2026
Alexandria Hammond
Wolfe Research
Buy
Upgraded
300,00 US$
+14,7%
08/13/2026
Emily Field
Barclays
Buy
Reiterated
300,00 US$
+14,7%
08/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
260,00 US$
-0,6%
08/10/2026
Hans Engel
Erste Group
Buy
Upgraded
-
-
08/05/2026
Vamil Divan
Guggenheim
Buy
Reiterated
288,00 US$
+10,1%
08/03/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
296,00 US$
+13,2%
08/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
285,00 US$
+8,9%
07/31/2026
Courtney Breen
Bernstein
Hold
Maintained
225,00 US$
-14%
07/22/2026
Asad Haider
Goldman Sachs
Hold
Maintained
244,00 US$
-6,7%
07/21/2026
Michael Yee
UBS
Hold
Reiterated
260,00 US$
-0,6%
07/13/2026
Michael Harvey
RBC Capital
Buy
Reiterated
280,00 US$
+7%
07/10/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
280,00 US$
+7%
06/23/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
280,00 US$
+7%
06/23/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
250,00 US$
-4,4%
05/13/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
262,00 US$
+0,2%
04/20/2026
Nico Chen
DBS
Hold
Maintained
230,00 US$
-12,1%
02/25/2026
Last report
31 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
3,65 US$ / 3,61 US$
+1,08%beat
Revenue / Est. (USD)
16,99 მლრდ. / 16,76 მლრდ.
+1,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
15,78 მლრდ.
16,62 მლრდ.
15,00 მლრდ.
16,99 მლრდ.
Cost of goods sold
4,46 მლრდ.
4,55 მლრდ.
4,22 მლრდ.
4,29 მლრდ.
Cost of revenue
4,46 მლრდ.
4,55 მლრდ.
4,22 მლრდ.
4,29 მლრდ.
Research and development expenses
2,29 მლრდ.
2,58 მლრდ.
2,47 მლრდ.
2,34 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,43 მლრდ.
3,82 მლრდ.
3,49 მლრდ.
3,55 მლრდ.
Operating expense
5,72 მლრდ.
6,40 მლრდ.
5,96 მლრდ.
5,90 მლრდ.
Total operating expenses
10,18 მლრდ.
10,95 მლრდ.
10,18 მლრდ.
10,19 მლრდ.
Operating income
5,60 მლრდ.
5,67 მლრდ.
4,82 მლრდ.
6,80 მლრდ.
Other non operating income
199,00 მლნ.
120,00 მლნ.
-3,00 მლნ.
-55,00 მლნ.
EBT including unusual items
714,00 მლნ.
2,67 მლრდ.
1,04 მლრდ.
4,28 მლრდ.
EBT excluding unusual items
5,11 მლრდ.
5,12 მლრდ.
4,19 მლრდ.
6,07 მლრდ.
Income tax expense
526,00 მლნ.
853,00 მლნ.
342,00 მლნ.
662,00 მლნ.
Effective tax rate
73,67%
31,97%
32,92%
15,47%
Other operating expenses
-
-
-
-
Net income
186,00 მლნ.
1,82 მლრდ.
695,00 მლნ.
3,61 მლრდ.
Net profit margin
1,18%
10,93%
4,63%
21,27%
Earnings per share
1,86
2,71
2,65
3,65
Interest and investment income
72,00 მლნ.
59,00 მლნ.
72,00 მლნ.
67,00 მლნ.
Interest expense
-739,00 მლნ.
-714,00 მლნ.
-717,00 მლნ.
-746,00 მლნ.
Net interest expenses
-667,00 მლნ.
-655,00 მლნ.
-645,00 მლნ.
-679,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
7,66 მლრდ.
7,66 მლრდ.
6,76 მლრდ.
8,68 მლრდ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები